FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610540653> ?p ?o ?g. }

• W2610540653 endingPage "3183" @default.
• W2610540653 startingPage "3175" @default.
• W2610540653 abstract "Abstract Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D). Seventy-nine patients with various NHL histologies, including diffuse large B-cell lymphoma, Richter’s transformation, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia, were enrolled. In the dose-escalation phase, patients received 3 to 80 mg/m2 of selinexor in 3- or 4-week cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity. In the dose-expansion phase, patients were treated with selinexor at 35 or 60 mg/m2. The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%). Tumor biopsies showed decreases in cell-signaling pathways (Bcl-2, Bcl-6, c-Myc), reduced proliferation (Ki67), nuclear localization of XPO1 cargos (p53, PTEN), and increased apoptosis after treatment. Twenty-two (31%) of the 70 evaluable patients had an objective responses, including 4 complete responses and 18 partial responses, which were observed across a spectrum of NHL subtypes. A dose of 35 mg/m2 (60 mg) was identified as the RP2D. These findings suggest that inhibition of XPO1 with oral selinexor at 35 mg/m2 is a safe therapy with encouraging and durable anticancer activity in patients with R/R NHL. The trial was registered at www.clinicaltrials.gov as #NCT01607892." @default.
• W2610540653 created "2017-05-12" @default.
• W2610540653 creator A5000885506 @default.
• W2610540653 creator A5009364549 @default.
• W2610540653 creator A5011559739 @default.
• W2610540653 creator A5017335587 @default.
• W2610540653 creator A5022339242 @default.
• W2610540653 creator A5033009352 @default.
• W2610540653 creator A5033974204 @default.
• W2610540653 creator A5036560661 @default.
• W2610540653 creator A5040141808 @default.
• W2610540653 creator A5049400849 @default.
• W2610540653 creator A5051352882 @default.
• W2610540653 creator A5056314507 @default.
• W2610540653 creator A5070373312 @default.
• W2610540653 creator A5071023119 @default.
• W2610540653 creator A5071420169 @default.
• W2610540653 creator A5074654320 @default.
• W2610540653 creator A5077110117 @default.
• W2610540653 creator A5082283453 @default.
• W2610540653 creator A5083579907 @default.
• W2610540653 creator A5083858828 @default.
• W2610540653 date "2017-06-15" @default.
• W2610540653 modified "2023-10-16" @default.
• W2610540653 title "Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma" @default.
• W2610540653 cites W1020989877 @default.
• W2610540653 cites W1822166136 @default.
• W2610540653 cites W1975428611 @default.
• W2610540653 cites W1982727560 @default.
• W2610540653 cites W1987452803 @default.
• W2610540653 cites W1997353354 @default.
• W2610540653 cites W1999990171 @default.
• W2610540653 cites W2006971960 @default.
• W2610540653 cites W2008743974 @default.
• W2610540653 cites W2011275571 @default.
• W2610540653 cites W2015798544 @default.
• W2610540653 cites W2018071905 @default.
• W2610540653 cites W2019874087 @default.
• W2610540653 cites W2020789296 @default.
• W2610540653 cites W2026374501 @default.
• W2610540653 cites W2046497407 @default.
• W2610540653 cites W2061782012 @default.
• W2610540653 cites W2086280295 @default.
• W2610540653 cites W2096764404 @default.
• W2610540653 cites W2096849855 @default.
• W2610540653 cites W2096850086 @default.
• W2610540653 cites W2099348990 @default.
• W2610540653 cites W2115694405 @default.
• W2610540653 cites W2117692326 @default.
• W2610540653 cites W2119680582 @default.
• W2610540653 cites W2125616358 @default.
• W2610540653 cites W2128936398 @default.
• W2610540653 cites W2133201432 @default.
• W2610540653 cites W2133345449 @default.
• W2610540653 cites W2138484914 @default.
• W2610540653 cites W2140485109 @default.
• W2610540653 cites W2141920998 @default.
• W2610540653 cites W2142099365 @default.
• W2610540653 cites W2144763856 @default.
• W2610540653 cites W2150099906 @default.
• W2610540653 cites W2153558008 @default.
• W2610540653 cites W2153944703 @default.
• W2610540653 cites W2158267770 @default.
• W2610540653 cites W2159862107 @default.
• W2610540653 cites W2168543296 @default.
• W2610540653 cites W2172003817 @default.
• W2610540653 cites W2207853596 @default.
• W2610540653 cites W2290633618 @default.
• W2610540653 cites W2337845158 @default.
• W2610540653 cites W2495597122 @default.
• W2610540653 doi "https://doi.org/10.1182/blood-2016-11-750174" @default.
• W2610540653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28468797" @default.
• W2610540653 hasPublicationYear "2017" @default.
• W2610540653 type Work @default.
• W2610540653 sameAs 2610540653 @default.
• W2610540653 citedByCount "113" @default.
• W2610540653 countsByYear W26105406532017 @default.
• W2610540653 countsByYear W26105406532018 @default.
• W2610540653 countsByYear W26105406532019 @default.
• W2610540653 countsByYear W26105406532020 @default.
• W2610540653 countsByYear W26105406532021 @default.
• W2610540653 countsByYear W26105406532022 @default.
• W2610540653 countsByYear W26105406532023 @default.
• W2610540653 crossrefType "journal-article" @default.
• W2610540653 hasAuthorship W2610540653A5000885506 @default.
• W2610540653 hasAuthorship W2610540653A5009364549 @default.
• W2610540653 hasAuthorship W2610540653A5011559739 @default.
• W2610540653 hasAuthorship W2610540653A5017335587 @default.
• W2610540653 hasAuthorship W2610540653A5022339242 @default.
• W2610540653 hasAuthorship W2610540653A5033009352 @default.
• W2610540653 hasAuthorship W2610540653A5033974204 @default.
• W2610540653 hasAuthorship W2610540653A5036560661 @default.
• W2610540653 hasAuthorship W2610540653A5040141808 @default.
• W2610540653 hasAuthorship W2610540653A5049400849 @default.
• W2610540653 hasAuthorship W2610540653A5051352882 @default.
• W2610540653 hasAuthorship W2610540653A5056314507 @default.
• W2610540653 hasAuthorship W2610540653A5070373312 @default.
• W2610540653 hasAuthorship W2610540653A5071023119 @default.

• next